Randomized Trial of ATN-224 and Temozolomide in Advanced Melanoma
Public ClinicalTrials.gov record NCT00383851. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized Phase II Trial of ATN-224 in Combination With Temozolomide or Temozolomide Followed by ATN-224 in Patients With Advanced Melanoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a multicenter, randomized, phase II study to evaluate the safety and efficacy of oral ATN-224 plus temozolomide in patients with advanced melanoma. Patients will be randomized (1:1) between temozolomide and ATN-224 and temozolomide followed by ATN-224. Patients assigned to the sequential treatment group will receive temozolomide until progression of disease is documented and then receive ATN-224 as a single agent until documentation of progression of disease using the last tumor assessment on temozolomide therapy as the baseline assessment.
Study identification
- NCT ID
- NCT00383851
- Recruitment status
- Not listed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 60 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2006
- Primary completion
- Not listed
- Completion
- Aug 31, 2008
- Last update posted
- Dec 5, 2007
2006 – 2008
United States locations
- U.S. sites
- 17
- U.S. states
- 12
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Cancer Center | Tucson | Arizona | 85724 | — |
| Pacific Oncology and Hematology | Encinitas | California | 92024 | — |
| Hematology - Oncology Group of Orange, Inc. | Orange | California | 92868 | — |
| UCI Chao Family Comprehensive Cancer Center | Orange | California | 92868 | — |
| The Angeles Clinic | Santa Monica | California | 90404 | — |
| University of Colorado Health Science Center | Denver | Colorado | 80262 | — |
| Florida Cancer Specialists | Fort Myers | Florida | 33901 | — |
| Hematology and Oncology Specialists, LLC | Metairie | Louisiana | 70006 | — |
| The Harry and Jeanette Weinberg Cancer Institute at Franklin Square | Baltimore | Maryland | 21237 | — |
| Center for Cancer and Blood Disorders | Bethesda | Maryland | 20817 | — |
| Billings Clinic | Billings | Montana | 59101 | — |
| Mountainside Hospital Cancer Center - The Melanoma Center | Montclair | New Jersey | 07042 | — |
| Oncology Hematology Care | Cincinati | Ohio | 45242 | — |
| Cancer Center of the Carolinas | Greenville | South Carolina | 29605 | — |
| Chattanooga Oncology and Hematology Associates | Chattanooga | Tennessee | — | — |
| Tennessee Oncology | Nashville | Tennessee | 37203 | — |
| Mary Crowley Medical Research Center | Dallas | Texas | 75246 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00383851, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 5, 2007 · Synced Sep 9, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00383851 live on ClinicalTrials.gov.